In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 EMAIL TO FRIEND     |      PRINTER FRIENDLY     |    
          advertisement

Protein Clumps May Appear Years Before Memory Problems

July 29 (HealthDay News) -- Amyloid protein deposits in the brain play a role in disrupting the memory formation process long before a person shows symptoms of the memory impairment of Alzheimer's disease, a new study contends.

Previous research had suggested that clumps of amyloid protein, which damage neurons and are characteristic of Alzheimer's disease, begin appearing many years before Alzheimer's symptoms appear. But the link between the deposits and memory impairment had not been clearly demonstrated in humans.

In the new study, which appears in the July 30 issue of Neuron, U.S. researchers used medical imaging to examine the brains of older people who did not have significant memory impairment.

"Two recent advances in neuroimaging now allow us to explore the early, asymptomatic phase of [Alzheimer's disease], the ability to measure amyloid distribution in living humans and the identification of sensitive markers of brain dysfunction" in the disease, Dr. Reisa Sperling, of the Center for Alzheimer's Research and Treatment at Brigham and Women's Hospital in Boston and lead author of the study, said in a news release from the journal's publisher.

The researchers found that a number of study participants had amyloid deposits and abnormal activity in areas of the brain believed to be involved in memory function.

The results could help in efforts to find ways to predict and treat cognitive decline in people at risk for Alzheimer's, the study authors noted.

"Longitudinal studies are certainly needed, but our findings are consistent with the premise that cognitively intact older individuals with amyloid pathology may already be in the early stages of [Alzheimer's disease]," Sperling said. "The combination of molecular and functional imaging techniques may prove useful in monitoring disease progression prior to significant clinical symptoms, as well as the response to amyloid-modifying therapeutic agents in subjects at risk for developing [Alzheimer's disease]."


SOURCE: Cell Press, news release, July 29, 2009

advertisement

Advice from Dr. Nancy Snyderman

Dr. Nancy Snyderman

Helpful tips and information on weight loss

Get answers from an expert
advertisement

YourTotalHealth      

Home  |  Health Centers  |  Health A-Z  |  Staying Healthy  |  Diet & Fitness  |  Woman & Family  |  Pregnancy  |  Community  |  

also on iVillage: Pregnancy & Parenting  |  Beauty & Style  |  Home & Garden  |  Food  |  Weddings  |  Love  |  Entertainment  |  NeverSayDiet

Terms of Service  |  Privacy Policy  |  Site Map  |  Newsletters  |  Feedback

Copyright (c) 2000-2009 iVillage Inc. All rights reserved. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.